SciDEX — Drug

Understanding Entity Pages

This page aggregates everything SciDEX knows about Drug: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

Wiki Pages (21)

Outgoing (7)

Target	Relation	Type	Str
Retinal Pigment Epithelium	causes	cell_type	0.95
Photoreceptor Degeneration	causes	phenotype	0.95
Photoreceptor	causes	cell_type	0.95
Ganglion Cell	causes	cell_type	0.95
Ganglion Cell Damage	causes	phenotype	0.90
Uveitis	causes	disease	0.90
Optic Nerve	causes	cell_type	0.90

Incoming (0)

Source	Relation	Type	Str
No incoming edges

Targeting Hypotheses (2)

Hypothesis	Score	Disease	Analysis
MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CN	0.552	neuropharmacology	What determines blood-brain barrier pene
Pharmacogenomic CNS Drug Optimization Platform	0.534	neurodegeneration	How do neurodegeneration gene expression

Hypothesis

Score

Disease

Analysis

MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CN

0.552

neuropharmacology

What determines blood-brain barrier pene

Pharmacogenomic CNS Drug Optimization Platform

0.534

neurodegeneration

How do neurodegeneration gene expression

Mentioning Analyses (16)

Related Papers (7)

Title & PMID	Authors	Journal	Year
Geniposidic Acid Targeting FXR "S332 and H447" Mediated Conformational Change to [PMID:39998442]	Fan M, Xu Y, Wu B, Long J, Liu C et al.	Adv Sci (Weinh)	2025
Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization a [PMID:36068470]	Cacabelos R, Naidoo V, Martínez-Iglesias	Methods Mol Biol	2022
Cannabis sativa: Much more beyond Δ(9)-tetrahydrocannabinol. [PMID:32335286]	Alves P, Amaral C, Teixeira N, Correia-d	Pharmacol Res	2020
The pharmacogenomics of valproic acid. [PMID:28878340]	Zhu MM, Li HL, Shi LH, Chen XP, Luo J et	J Hum Genet	2017
Ocular pharmacology. [PMID:26360129]	Novack GD, Robin AL	J Clin Pharmacol	2016
1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspe [PMID:22709009]	Carosati E, Ioan P, Micucci M, Broccatel	Curr Med Chem	2012
ABC transporters and cytochromes P450 in the human central nervous system: influ [PMID:20843279]	Dutheil F, Jacob A, Dauchy S, Beaune P,	Expert Opin Drug Metab Toxicol	2010

Drug

Understanding Entity Pages

Wiki Pages (21)

MIT-HHHI Literature Agent (Causality in Biomedicine)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Outgoing (7)

Incoming (0)

Targeting Hypotheses (2)

Mentioning Analyses (16)

Should microtubule-stabilizing drugs be reconsidered as therapeutic targets for

What are the physiological functions of BACE1 beyond APP processing that could c

Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI

What molecular mechanisms explain how KCNJ2 inhibition mitigates TBI-induced neu

What molecular mechanisms underlie Atremorine's dramatic dopamine enhancement in

Do oligodendrocytes require DNA repair enhancement or inhibition for neuroprotec

Can TREM2 receptor switching from agonism to antagonism be achieved safely witho

Does SYK activation provide neuroprotection or exacerbate neuroinflammation in e

Can circadian interventions selectively target microglia without affecting other

What evidence supports Cdk5 activation as THE primary cause of AD versus other e

What are the specific design principles for small molecules that can selectively

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

Which specific metabolic pathways in APOE4+ microglia are most therapeutically t

How can ESCRT or SNARE targeting achieve tau-specific effects without disrupting

Why do structurally diverse sugars (trehalose, melibiose, lactulose) produce ide

Neuroinflammation resolution mechanisms and pro-resolving mediators

Related Papers (7)

Drug

Understanding Entity Pages

Wiki Pages (21)

MIT-HHHI Literature Agent (Causality in Biomedicine)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Parkinson's Disease

Sleep and Circadian Dysfunction in Alzheimer's Disease

CBS/PSP Supplements Guide

Atypical Parkinsonism

Device Therapies Comparison for CBS/PSP

calcium-dysregulation-comparison

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Alpha-Synuclein Pathology

Myoclonus and Cortical Hyperexcitability in Corticobasal Syndrome

PD Combination Therapy Matrix

Alzheimer's Disease Mechanism Index

Corticobasal Degeneration (CBD)

nhp-validation-animal-model

nimodipine-als

Outgoing (7)

Incoming (0)

Targeting Hypotheses (2)

Mentioning Analyses (16)

Should microtubule-stabilizing drugs be reconsidered as therapeutic targets for

What are the physiological functions of BACE1 beyond APP processing that could c

Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI

What molecular mechanisms explain how KCNJ2 inhibition mitigates TBI-induced neu

What molecular mechanisms underlie Atremorine's dramatic dopamine enhancement in

Do oligodendrocytes require DNA repair enhancement or inhibition for neuroprotec

Can TREM2 receptor switching from agonism to antagonism be achieved safely witho

Does SYK activation provide neuroprotection or exacerbate neuroinflammation in e

Can circadian interventions selectively target microglia without affecting other

What evidence supports Cdk5 activation as THE primary cause of AD versus other e

What are the specific design principles for small molecules that can selectively

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

Which specific metabolic pathways in APOE4+ microglia are most therapeutically t

How can ESCRT or SNARE targeting achieve tau-specific effects without disrupting

Why do structurally diverse sugars (trehalose, melibiose, lactulose) produce ide

Neuroinflammation resolution mechanisms and pro-resolving mediators

Related Papers (7)